A first-in-class, first-in-human, phase i trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1061-1070

  Warso, M A ^a   Richards, J M ^b   Mehta, D ^a   Christov, K ^a   Schaeffer, C ^a   Rae Bressler, L ^a   Yamada, T ^a   Majumdar, D ^a   Kennedy, S A ^c   Beattie, C W ^a   Das Gupta, T K ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Oncology Specialists   (United States)

^c UNIVERSITY OF ILLINOIS HOSPITAL AND HEALTH SCIENCES SYSTEM   (United States)

Author keywords

metastatic solid tumours; p28; p53

Indexed keywords

PROTEIN P28; PROTEIN P53;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CONTROL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; MAXIMUM TOLERATED DOSE; OVERALL SURVIVAL; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOLID TUMOR; STEADY STATE; UBIQUITINATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; AZURIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PEPTIDE FRAGMENTS; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

EID: 84875420696     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.74     Document Type: Article

References (40)

1. Alexandroff AB, Jackson AM, O'Donnell MA, James K (1999) BCGimmunotherapy of bladder cancer: 20 years on. Lancet 353 (9165) :1689-1694.
2. Anderson KC, Hannah AL, Pazdur R, Farrell AT (2007) A strategicframework for novel drug development in multiple myeloma. Br JHaematol 138 (2) : 153-159.
3. Andreeff M, Kojima K, Padmanabhan S, Strair R, Kirschbaum M, Maslak P, Hillmen P, O'Brien S, Samaniego F, Borthakur G, Konopleva M, Vassilev L, Nichols G (2010) A multi-center, open-label, phase i study ofsingle agent RG7112, A first in class p53-MDM2 antagonist, in patientswith relapsed/refractory acute myeloid and lymphoid leukemias (AML/ALL) and refractory chronic lymphocytic leukemia/small cell lymphocyticlymphomas (CLL/SCLL) . Blood (ASH Annual Meeting Abstracts) 116: 657.
4. Arkenau HT, Olmos D, Ang JE, Barriuso J, Karavasilis V, Ashley S, de Bono J, Judson I, Kaye S ( 2008) 90-Days mortality rate in patients treated withinthe context of a phase-I trial how should we identify patients who shouldnot go on trial? Eur J Cancer 44 (11) : 1536-1540.
5. Bizzarri AR, Santini S, Coppari E, Bucciantini M, Di Agostino S, Yamada T, Beattie CW, Cannistraro S (2011) Interaction of an anticancer peptidefragment of azurin with p53 and its isolated domains studied by atomicforce spectroscopy. Int J Nanomed 6: 3011-3019.
6. Bullock AN, Fersht AR (2001) Rescuing the function of mutant p53. Nat RevCancer 1 (1) : 68-76.
7. Chau NG, Florescu A, Chan KK, Wang L, Chen EX, Bedard P, Oza AM, Siu LL (2011) Early mortality and overall survival in oncology phase I trialparticipantscan we improve patient selection? BMC Cancer 11: 426.
8. Chaudhari A, Mahfouz M, Fialho AM, Yamada T, Granja AT, Zhu Y, Hashimoto W, Schlarb-Ridley B, Cho W, Das Gupta TK, Chakrabarty AM (2007) Cupredoxin-cancer interrelationship: azurin binding with EphB2, interference in EphB2 tyrosine phosphorylation, and inhibition of cancergrowth. Biochemistry 46 (7) : 1799-1810.
9. Coley WB (1891) The treatment of malignant tumors by repeated inoculationsof erysipelas. With a report of ten original cases. Clin Orthop Relat Res262: 3-12.
10. Coley WB (1911) Surg Gynec Obstet 613 174-190.
11. da Rocha AB, Lopes RM, Schwartsmann G (2001) Natural products inanticancer therapy. Curr Opin Pharmacol 1 (4) : 364-369.
12. Dasgupta TK, Brasfield RD (1964) Metastatic melanoma of thegastrointestinal tract. Arch Surg 88: 969-973.
13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluationcriteria in solid tumours: revised RECIST guideline (version 1.1) . Eur JCancer 45 (2) : 228-247.
14. Faivre S, Zappa M, Vilgrain V, Boucher E, Douillard JY, Lim HY, Kim JS, Im SA, Kang YK, Bouattour M, Dokmak S, Dreyer C, Sablin MP, Serrate C, Cheng AL, Lanzalone S, Lin X, Lechuga MJ, Raymond E (2011) Changes in tumor density in patients with advanced hepatocellularcarcinoma treated with sunitinib. Clin Cancer Res 17 (13) : 4504-4512.
15. Gorman GS, Coward LU, Freeman L, Noker PE, Beattie CW, Jia L (2010) A novel and rapid LC/MS/MS assay for bioanalysis of Azurin p28 in serumand its pharmacokinetics in mice. J Pharm Biomed Anal 53 (4) : 991-996.
16. Hiraoka Y, Granja AT, Fialho AM, Schlarb-Ridley BG, Das Gupta TK, Chakrabarty AM, Yamada T (2005) Human cytochrome c enters murineJ774 cells and causes G1 and G2/M cell cycle arrest and induction ofapoptosis. Biochem Biophys Res Commun 338 (2) : 1284-1290.
17. Jia L, Gorman GS, Coward LU, Noker PE, McCormick D, Horn TL, HarderJB, Muzzio M, Prabhakar B, Ganesh B, Das Gupta TK, Beattie CW (2011) Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer ChemotherPharmacol 68 (2) : 513-524.
18. Lara-Guerra H, Waddell TK, Salvarrey MA, Joshua AM, Chung CT, Paul N, Boerner S, Sakurada A, Ludkovski O, Ma C, Squire J, Liu G, Shepherd FA, Tsao MS, Leighl NB (2009) Phase II study of preoperative gefitinib inclinical stage I non-small-cell lung cancer. J Clin Oncol 27 (36) : 6229-6236.
19. Martin AC, Facchiano AM, Cuff AL, Hernandez-Boussard T, Olivier M, Hainaut P, Thornton JM (2002) Integrating mutation data and structuralanalysis of the TP53 tumor-suppressor protein. Hum Mutat 19 (2) :149-164.
20. Mehta RR, Yamada T, Taylor BN, Christov K, King ML, Majumdar D, Lekmine F, Tiruppathi C, Shilkaitis A, Bratescu L, Green A, Beattie CW, Das Gupta TK (2011) A cell penetrating peptide derived from azurininhibits angiogenesis and tumor growth by inhibiting phosphorylation ofVEGFR-2, FAK and Akt. Angiogenesis 14 (3) : 355-369.
21. Miao XD, Ye ZM, Yang DS, Xu RZ, Li WX, Tao HM (2005) [Cytotoxicity andapoptosis of human osteosarcoma U2OS cells induced by recombinantsoluble AZURIN]. Zhejiang Da Xue Xue Bao Yi Xue Ban 34 (5) : 384-389.
22. Midgley CA, Lane DP (1997) p53 protein stability in tumour cells is notdetermined by mutation but is dependent on Mdm2 binding. Oncogene15 (10) : 1179-1189.
23. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P (2002) TheIARC TP53 database: new online mutation analysis and recommendationsto users. Hum Mutat 19 (6) : 607-614.
24. Paglia P, Guzman CA (1998) Keeping the immune system alerted againstcancer. Cancer Immunol Immunother 46 (2) : 88-92.
25. Penel N, Delord JP, Bonneterre ME, Bachelot T, Ray-Coquard I, Blay JY, Pascal LB, Borel C, Filleron T, Adenis A, Bonneterre J (2010) Development and validation of a model that predicts early death amongcancer patients participating in phase I clinical trials investigatingcytotoxics. Invest New Drugs 28 (1) : 76-82.
26. Punj V, Bhattacharyya S, Saint-Dic D, Vasu C, Cunningham EA, Graves J, Yamada T, Constantinou AI, Christov K, White B, Li G, Majumdar D, Chakrabarty AM, Das Gupta TK (2004) Bacterial cupredoxin azurin as aninducer of apoptosis and regression in human breast cancer. Oncogene23 (13) : 2367-2378.
27. Ramakrishna R, Barber J, Kennedy G, Rizvi A, Goodkin R, Winn RH, Ojemann GA, Berger MS, Spence AM, Rostomily RC (2010) Imagingfeatures of invasion and preoperative and postoperative tumor burden inpreviously untreated glioblastoma: Correlation with survival. Surgicalneurology international 1 (pii) : 40.
28. Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC (1997) Accelerated titration designs for phase I clinical trials in oncology. J NatlCancer Inst 89 (15) : 1138-1147.
29. Tabernero J, Dirix L, Schoffski P, Cervantes A, Capdevila J, Baselga J, vanBeijsterveldt L, Winkler H, Kraljevic S, Zhuang SH (2009) Phase Ipharmacokinetic (PK) and pharmacodynamic (PD) study of HDM-2antagonist JNJ-26854165 in patients with advanced refractory solidtumors. J Clin Oncol 27: 15.
30. Tan YH, Chen YM, Ye X, Lu Q, Tretyachenko-Ladokhina V, Yang W, Senear DF, Luo R (2009) Molecular mechanisms of functional rescuemediated by P53 tumor suppressor mutations. Biophys Chem 145 (1) :37-44.
31. Taylor BN, Mehta RR, Yamada T, Lekmine F, Christov K, Chakrabarty AM, Green A, Bratescu L, Shilkaitis A, Beattie CW, Das Gupta TK (2009) Noncationic peptides obtained from azurin preferentially enter cancercells. Cancer Res 69 (2) : 537-546.
32. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0:development of a comprehensive grading system for the adverse effects ofcancer treatment. Semin Radiat Oncol 13 (3) : 176-181.
33. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA (2004) In vivoactivation of the p53 pathway by small-molecule antagonists of MDM2.Science 303 (5659) : 844-848.
34. Vickers AJ (2006) How to design a phase I trial of an anticancer botanical.J Soc Integr Oncol 4 (1) : 46-51.
35. Vickers AJ, Kuo J, Cassileth BR (2006) Unconventional anticancer agents: asystematic review of clinical trials. J Clin Oncol 24 (1) : 136-140.
36. Yamada T, Goto M, Punj V, Zaborina O, Chen ML, Kimbara K, Majumdar D, Cunningham E, Das Gupta TK, Chakrabarty AM (2002) Bacterial redoxprotein azurin, tumor suppressor protein p53, and regression of cancer.Proc Natl Acad Sci USA 99 (22) : 14098-14103.
37. Yamada T, Mehta RR, Lekmine F, Christov K, King ML, Majumdar D, Shilkaitis A, Green A, Bratescu L, Beattie CW, Das Gupta TK (2009) Apeptide fragment of azurin induces a p53-mediated cell cycle arrest inhuman breast cancer cells. Mol Cancer Ther 8 (10) : 2947-2958.
38. Yang DS, Miao XD, Ye ZM, Feng J, Xu RZ, Huang X, Ge FF (2005) Bacterialredox protein azurin induce apoptosis in human osteosarcoma U2OS cells.Pharmacol Res 52 (5) : 413-421.
39. Ye ZM, Miao XD, Yang DS, Xu RZ, Huang X, Ge FF (2005) [Selectiveinducement effect of bacterial redox protein azurin on apoptosis of humanosteosarcoma cell line U2OS]. Ai zheng 24 (3) : 298-304.
40. Zhang H (1999) Evaluation of four antibodies in detecting p53 protein forpredicting clinicopathological and prognostic significance in colorectaladenocarcinoma. Clin Cancer Res 5 (12) : 4126-4132.